Apogee Therapeutics initiated with a Peer Perform at Wolfe Research

Wolfe Research initiated coverage of Apogee Therapeutics (APGE) with a Peer Perform rating and no price target While asthma appeared to have been a minor catalyst, any future success could have long-term implications, the analyst tells investors. However, with that said, “convenience euphoria has blasted the stock to all-time highs,” adds the analyst, who foresees two negative catalysts in the first half of the year, followed by a high-conviction positive catalyst in the second half.